With a top treatment recommendation for obese women with polycystic ovary syndrome (PCOS) comprising lifestyle changes via diet changes and physical activity, this study’s investigators evaluated the effects of a ketogenic diet among this patient population.
As a first-stage nonpharmacological treatment for women with polycystic ovary syndrome (PCOS) who are classified as obese, the ketogenic diet—in particular, caloric restriction—shows great promise as adjuvant treatment alongside pharmacological therapy, note new study findings in the International Journal of Environmental Research and Public Health.
Common comorbidities of PCOS are insulin resistance, dyslipidemia, and obesity, the authors noted, which can increase the risk of diabetes and metabolic syndrome among women with the endocrine disorder. Seventeen women whose mean (SD) age was 28.5 (5.38) years (fertile age, according to the investigators) with PCOS and who were classified as obese (body mass index [BMI] > 25) were included in this study; all were enrolled at the University Medical Service of Dietetic and Metabolic Diseases of the Faculty of Medicine and Surgery of the University of Foggia, in Italy.
“In light of this evidence, the most therapeutic option prescribed to obese women with PCOS, regardless of the phenotype and the severity of clinical expression, is lifestyle correction,” they wrote. “This is the first study on the effects of the ketogenic diet on PCOS.” This type of diet consists of increased fat intake, reduced carbohydrate intake, and adequate protein. For this study, daily intakes were set at 600 kcal for calories, 1.1 to 1.2 g of protein per kilogram body weight, 30 g for carbohydrates, and 30 g for fats.
Following a 45-day dietary protocol, baseline/first visit findings were compared with 45-day/final visit results for gynecological evaluation of oligo/amenorrhea status, nutritional status, body composition, biochemical measurements, and diet administration. The baseline overall average total body weight was 81.5 (13.56) kg and the baseline BMI, 31.84 (5.85) kg/m2.
Decreases were seen in all of the following measures:
Improvements were also seen in several of the metabolic parameters (all P < .001):
For endocrine parameters, these changes were seen:
In addition, regular menstrual cycles reappeared in 5 patients, “after years of amenorrhea,” the authors noted, while regular menstrual cycles were restored for the other 12 patients—5 of whom when on to become pregnant naturally.
“The results attest that the mixed dietary ketogenic medical intervention, by reducing the amount of carbohydrates and inducing therapeutic ketosis, acts favorably and effectively in the management of PCOS,” they wrote. “These data are very interesting and showed that this pathology is a multifactorial disease influenced by lifestyle.”
The authors further concluded that their results are buffeted by the fact that their ketogenic diet intervention saw such positive results in such a short period and that this was seen without the addition of foods meant to induce weight loss. And although they recommend a ketogenic diet as adjuvant treatment with pharmacological therapy for PCOS, they do suggest additional studies are needed on the mechanisms the propel the benefits a this diet.
Reference
Cincione RI, Losavio F, Ciolli, et al. Effects of mixed of a ketogenic diet in overweight and obese women with polycystic ovary syndrome. Int J Environ Res Public Health. Published online November 27, 2021. doi:10.3390/ijerph182312490
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More